American Society of Hematology

Figure 6.

211At-CD38 therapy in a disseminated OPM-2 Luc model. Mice bearing disseminated OPM-2Luc xenografts were treated on day 0 with 211At-CD38 or 211At-Ab− at 15, 30, or 45 µCi; n = 9 to 10 mice per group. Disease progression was monitored via weekly BLI and thrice weekly observations of mouse weight, condition, and mobility. Mice were euthanized when they experienced hind-limb paralysis or met IACUC weight loss or condition requirements. (A) BLI of untreated control and 15 µCi treatment groups at 21 days posttherapy. (B) BLI of all groups at 41 days posttherapy. Red coffins indicate deceased mice. BLI scale identical to panel A.

²¹¹At-CD38 therapy in a disseminated OPM-2 ^Lucmodel. Mice bearing disseminated OPM-2^Luc xenografts were treated on day 0 with ²¹¹At-CD38 or ²¹¹At-Ab⁻ at 15, 30, or 45 µCi; n = 9 to 10 mice per group. Disease progression was monitored via weekly BLI and thrice weekly observations of mouse weight, condition, and mobility. Mice were euthanized when they experienced hind-limb paralysis or met IACUC weight loss or condition requirements. (A) BLI of untreated control and 15 µCi treatment groups at 21 days posttherapy. (B) BLI of all groups at 41 days posttherapy. Red coffins indicate deceased mice. BLI scale identical to panel A.

This Feature Is Available To Subscribers Only